About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Trp53tm5Tyj
targeted mutation 5, Tyler Jacks
MGI:3702077
Summary 7 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
hm1
 		Trp53tm5Tyj/Trp53tm5Tyj involves: 129S4/SvJae MGI:3700134
cn2
 		Trp53tm5Tyj/Trp53tm5Tyj involves: 129S4/SvJae MGI:3717085
cn3
 		Krastm1.1Hbji/Krastm1.1Hbji
Trp53tm5Tyj/Trp53tm5Tyj 		involves: 129S4/SvJae MGI:5693626
cn4
 		Gt(ROSA)26Sortm1(cre/ERT2)Tyj/?
Trp53tm5Tyj/Trp53tm5Tyj 		involves: 129S4/SvJae * C57BL/6 MGI:3700133
cn5
 		Krastm4Tyj/Kras+
Scgb1a1tm1(cre/ERT)Blh/Scgb1a1+
Trp53tm5Tyj/Trp53+ 		involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 MGI:5317170
cn6
 		Krastm4Tyj/Kras+
Sftpctm1(cre/ERT2)Blh/Sftpc+
Trp53tm5Tyj/Trp53+ 		involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6 MGI:5317171
cx7
 		Gnl3Gt(W223E05)Wrst/Gnl3Gt(W223E05)Wrst
Trp53tm1Tyj/Trp53tm5Tyj 		involves: 129S2/SvPas * 129S4/SvJae MGI:3702081


Genotype
MGI:3700134
hm1
Allelic
Composition		 Trp53tm5Tyj/Trp53tm5Tyj
Genetic
Background		 involves: 129S4/SvJae
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Trp53tm5Tyj mutation (1 available); any Trp53 mutation (240 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
cellular
abnormal chromosome number ( J:118233 )
• marked genetic instability similar to that seen in Trp53tm1Tyj homozygous cells
abnormal cell cycle ( J:96433 )
• similar to Trp53 null cells, the percentage of cells in S phase is increased compared to wild-type cells
abnormal cell death ( J:96433 , J:118233 )
• in the absence of cre, MEFs are refractory to stress-induced cell death (J:96433)
• lack cell-culture-induced senescence (J:118233)




Genotype
MGI:3717085
cn2
Allelic
Composition		 Trp53tm5Tyj/Trp53tm5Tyj
Genetic
Background		 involves: 129S4/SvJae
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Trp53tm5Tyj mutation (1 available); any Trp53 mutation (240 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
cellular
cellular phenotype ( J:96433 )
N
• infection with adenoviral cre restores normal DNA damage-induce G1 arrest response and stress-induced apoptotic responses




Genotype
MGI:5693626
cn3
Allelic
Composition		 Krastm1.1Hbji/Krastm1.1Hbji
Trp53tm5Tyj/Trp53tm5Tyj
Genetic
Background		 involves: 129S4/SvJae
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm1.1Hbji mutation (0 available); any Kras mutation (84 available)
Trp53tm5Tyj mutation (1 available); any Trp53 mutation (240 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
cellular
increased fibroblast proliferation ( J:220921 )
• MEFs treated with adeno-cre and later with tamoxifen
• increased cell proliferation
• more cells at the G2/M phase of the cell cycle
• foci formation in 3D cell culture after tamoxifen treatment
• withdrawal of tamoxifen reduces colony formation

neoplasm
increased lung adenoma incidence ( J:220921 )
• mice treated with adeno-cre at 6-8 weeks of age and tamoxifen starting three weeks later
• tamoxifen doses of 100ug/mouse, 250ug/mouse, or 1000ug/mouse resulted in no lung abnormalities
• the intermediate dose of 500ug/mouse results in lung hyperplasia starting after 5 weeks of treatment
• lung adenomas found after 8 weeks of treatment
• tamoxifen treatment discontinued after 12 weeks and lung hyperplasia is decreased a weeks later
• lungs are normal 2 weeks after discontinuation of tamoxifen treatment

respiratory system
increased lung adenoma incidence ( J:220921 )
• mice treated with adeno-cre at 6-8 weeks of age and tamoxifen starting three weeks later
• tamoxifen doses of 100ug/mouse, 250ug/mouse, or 1000ug/mouse resulted in no lung abnormalities
• the intermediate dose of 500ug/mouse results in lung hyperplasia starting after 5 weeks of treatment
• lung adenomas found after 8 weeks of treatment
• tamoxifen treatment discontinued after 12 weeks and lung hyperplasia is decreased a weeks later
• lungs are normal 2 weeks after discontinuation of tamoxifen treatment




Genotype
MGI:3700133
cn4
Allelic
Composition		 Gt(ROSA)26Sortm1(cre/ERT2)Tyj/?
Trp53tm5Tyj/Trp53tm5Tyj
Genetic
Background		 involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(cre/ERT2)Tyj mutation (3 available); any Gt(ROSA)26Sor mutation (993 available)
Trp53tm5Tyj mutation (1 available); any Trp53 mutation (240 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
neoplasm
tumor regression ( J:118233 )
• mice with radiation-induced tumors that are subsequently treated with tamoxifen show tumor regression (7 of 10) or cessation of tumor progression (2 of 10)




Genotype
MGI:5317170
cn5
Allelic
Composition		 Krastm4Tyj/Kras+
Scgb1a1tm1(cre/ERT)Blh/Scgb1a1+
Trp53tm5Tyj/Trp53+
Genetic
Background		 involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm4Tyj mutation (9 available); any Kras mutation (84 available)
Scgb1a1tm1(cre/ERT)Blh mutation (1 available); any Scgb1a1 mutation (29 available)
Trp53tm5Tyj mutation (1 available); any Trp53 mutation (240 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
decreased tumor-free survival time ( J:182218 )
• animal succumb due to tumor burden at 20-24 weeks

neoplasm
increased lung adenoma incidence ( J:182218 )
• at 6-8 weeks of age, animals administered 4 doses of tamoxifen develop adenomas in the alveoli by 15 weeks; these progress to adenocarcinomas
• papillary adenomas are seen in alveoli at 15 and 21 weeks after tamoxifen treatment
increased adenocarcinoma incidence ( J:182218 )
• develop in alveoli and near the bronchioalveolar duct junction by 15 weeks of age with tamoxifen administration at 6-8 weeks
• larger bronchioles and non terminal bronchi appear normal
• advanced papillary adenocarcinomas are observed at 21 weeks after tamoxifen treatment

respiratory system
increased lung adenoma incidence ( J:182218 )
• at 6-8 weeks of age, animals administered 4 doses of tamoxifen develop adenomas in the alveoli by 15 weeks; these progress to adenocarcinomas
• papillary adenomas are seen in alveoli at 15 and 21 weeks after tamoxifen treatment
abnormal bronchoalveolar duct junction morphology ( J:182218 )
• hyperplasia is observed at 3 weeks after tamoxifen induction, and persists at 15 and 21 weeks




Genotype
MGI:5317171
cn6
Allelic
Composition		 Krastm4Tyj/Kras+
Sftpctm1(cre/ERT2)Blh/Sftpc+
Trp53tm5Tyj/Trp53+
Genetic
Background		 involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm4Tyj mutation (9 available); any Kras mutation (84 available)
Sftpctm1(cre/ERT2)Blh mutation (1 available); any Sftpc mutation (24 available)
Trp53tm5Tyj mutation (1 available); any Trp53 mutation (240 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:182218 )
• mice die 14 weeks or less after tamoxifen administration

neoplasm
increased lung adenoma incidence ( J:182218 )
• at 6-8 weeks of age, animals administered 1dose or 4 doses of tamoxifen develop widespread adenomas in the alveoli by 14 weeks of age, but the bronchoalveolar duct junction remains tumor-free
increased adenocarcinoma incidence ( J:182218 )
• at 6-8 weeks of age, animals administered 1dose or 4 doses of tamoxifen develop widespread adenocarcinomas in the alveoli by 14 weeks of age

respiratory system
increased lung adenoma incidence ( J:182218 )
• at 6-8 weeks of age, animals administered 1dose or 4 doses of tamoxifen develop widespread adenomas in the alveoli by 14 weeks of age, but the bronchoalveolar duct junction remains tumor-free
abnormal pulmonary alveolus morphology ( J:182218 )
• at 2 weeks after tamoxifen treatement, brochioalveolar duct junctions (BADJ) appear normal, but small adenomas occur in the alveoli; these progress to adenocarcinoma but the BADJ remain histologically normal




Genotype
MGI:3702081
cx7
Allelic
Composition		 Gnl3Gt(W223E05)Wrst/Gnl3Gt(W223E05)Wrst
Trp53tm1Tyj/Trp53tm5Tyj
Genetic
Background		 involves: 129S2/SvPas * 129S4/SvJae
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gnl3Gt(W223E05)Wrst mutation (0 available); any Gnl3 mutation (56 available)
Trp53tm1Tyj mutation (12 available); any Trp53 mutation (240 available)
Trp53tm5Tyj mutation (1 available); any Trp53 mutation (240 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
embryonic lethality during organogenesis, complete penetrance ( J:118144 )
• loss of Trp53 expression does not alter or delay the lethality

embryo
embryonic growth arrest ( J:118144 )
• loss of Trp53 expression does not alter or delay the overall phenotype

cellular
decreased cell proliferation ( J:118144 )
• loss of Trp53 expression does not alter or delay the impairment of cell proliferation




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
12/10/2024
MGI 6.24 		The Jackson Laboratory